California Stem Cell Agency Nixes ACT Grant Applications 15 Times
By Dr. Matthew Watson
(Editor's note: The assertion in this item that 15 applications by ACT were rejected by the California stem cell agency is incorrect, according to the venture capitalist who made the statement. He retracted it on the afternoon of April 12. His explanation can be found here. )
IRVINE, Ca. --The only firm in the nation conducting an ongoing hESC clinical trial has been rejected 15 times for funding by California's $3 billion stem cell agency.
The figure was reported yesterday at a hearing by the blue-ribbon Institute of Medicine panel looking into the performance of the stem cell agency, which has been sharply criticized in recent years for its paucity of industry funding.
Gregory Bonfiglio, managing partner in Proteus Regenerative Medicine, a stem cell venture capital firm in Portola Valley, Ca., disclosed the grant attempts by Advanced Cell Technology, whose nominal headquarters are in Santa Monica, Ca. Bonfiglio indicated that it was a high profile example of how CIRM is not taking the necessary steps to fulfill its goal of developing therapies that actually reach the clinic.
He noted that ACT received national attention in January when it posted favorable findings for its clinical trial at UCLA dealing with blindness but that the firm was still unable to win a CIRM grant over the last several years.
ACT had moved much of its operations to California in the wake of passage of Proposition 71, the measure that created the state's stem cell research effort in 2004. It has since re-centered its operations in Massachusetts.
The California Stem Cell Report has queried ACT on its grant efforts and will carry its response verbatim when it is received.
Another firm, which cannot be identified, said privately yesterday that it was rejected 14 times.
According to our calculations based on figures this morning on the CIRM web site, businesses have received only $54.3 million in grants and loans during the last seven years, 4 percent of the $1.3 billion awarded. However, the CIRM list slightly understates the industry total. At least two other firms are sharing in two $20 million grants involving academic institutions, but are not noted on the list.
Yesterday's IOM meeting was the second and final California public session for the CIRM inquiry. Most of the day was occupied by a variety of critiques of the organization. The panel has already heard extensively from the agency itself and beneficiaries of its grants. The IOM report is expected in November.
Harold Shapiro, chairman of the panel and former president of Princeton University, described yesterday afternoon's panel involving stem cell business executives as "one of the more interesting" of the day.
One of the speakers was Michael West, CEO of Biotime in Alameda, which has received $4.7 million from CIRM. West, the founder of Geron, was also head of ACT when it moved it to California. He said CIRM had several "blind spots," including misconceptions about how products are made. For example, West said, CIRM's performance indicates that it does not fully understand that development leads directly to cures -- not research.
West said that if the high tech industry had to rely on CIRM-type funding years ago, laptops and iPads would still be in the lab instead of the marketplace.
The business industry representatives said that creation of CIRM has been beneficial for stem cell research, but cited a number of deficiencies in connection with industry applications.
In some ways, their comments echoed past remarks by several CIRM board members, who have expressed concern about the lack of funding for industry, as well as those of the agency's own external review panel. One issue raised by those CIRM directors has been the lack of grant reviewers with product development and industry expertise.
At yesterday's hearing, Gabriel Nistor, vice president of research and development at California Stem Cell in Irvine, said, it is "exceedingly rare to find academics (grant reviewers) that understand the complexities" involving industry. Nistor said his firm has applied for a "few" CIRM grants. None have been awarded.
Also speaking was Allan Robins, CEO of Viacyte in San Diego, who said his firm has done well with CIRM funding. It has received $26.2 million, nearly all of it in the form of a loan. But he said companies develop products – not academia.
Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
- 001 International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- 002 CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- 003 International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- 004 MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- 005 CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- 006 Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 007 More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- 008 International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- 009 CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- 010 International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 011 Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- 012 US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- 013 International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- 014 An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- 015 International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- 016 Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- 017 CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- 018 International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- 019 International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- 020 Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- 021 New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- 022 Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- 023 OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- 024 International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- 025 International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 026 California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 027 International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- 028 Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- 029 International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- 030 Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- 031 Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 032 More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- 033 International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- 034 Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- 035 Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- 036 Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- 037 International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- 038 Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- 039 Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]
- 040 International Stem Cell Corporation - Breakthrough Technology Alert [Last Updated On: August 6th, 2010] [Originally Added On: August 6th, 2010]
- 041 Oxygen, hypoxia and the stem cell niche [Last Updated On: August 7th, 2010] [Originally Added On: August 7th, 2010]
- 042 Partnership Pays Off [Last Updated On: August 17th, 2010] [Originally Added On: August 17th, 2010]
- 043 Video: Summary of Recent Developments in Stem Cell and Regenerative Medicine from Kenneth Aldrich, Chairman of International Stem Cell Corporation [Last Updated On: August 18th, 2010] [Originally Added On: August 18th, 2010]
- 044 International Stem Cell Corporation Formalizes Stem Cell Based Eye Care Programs into Cytovis™ [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 045 International Stem cell Corporation Chairman Discusses Recent Stem Cell Research Funding Decision [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 046 International Stem Cell Corporation Not Adversely Affected by Stem Cell Research Funding Ban [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 047 A Primer on the Use of Stem Cells in Ophthalmology by Irving J. Arons [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 048 Kenneth Aldrich, Chairman and Co-Founder of International Stem Cell Corporation will be making two public appearances this week on behalf of ISCO. [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 049 International Stem Cell Corporation Reports Significant Progress Towards Creation of the First Bank of Immune-Matched Human Parthenogenetic Stem Cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 050 International Stem Cell Corporation and Insight Bioventures India Structure Indian Affiliate to Develop Stem Cell-Based Eye Care Therapeutics... [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 051 ISCO to Present Data on Progress of Human Parthenogenetic Stem Cell Differentiation into Functional Liver Cells at the Annual Meeting... [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 052 Putative tumor-initiating progenitor cells predict poor lung cancer prognosis [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 053 Therapeutic implications of colon CSCs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 054 Selective targeting of neuroblastoma tumour-initiating cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 055 Two Open Access reviews [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 056 Isolation and killing of candidate CML stem cells by antibody targeting [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 057 Some breast cancer tumors may not originate from stem cells? [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 058 On the low frequency of tumor-initiating cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 059 Must the last CML cell be killed? [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 060 Critical molecular pathways in CSCs of CML [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 061 Insights into the stem cells of CML [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 062 International Stem Cell Corporation Announces Launch Plans for New Skin Care Products [Last Updated On: October 16th, 2010] [Originally Added On: October 16th, 2010]
- 063 International Stem Cell Corporation Announces Completion of Its First Manufacturing Run of Lifeline Skin Care's Stem Cell-Based Skin Rejuvenation... [Last Updated On: October 26th, 2010] [Originally Added On: October 26th, 2010]
- 064 Notes from The Chairman Concerning ISCO Price Fluctuations [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 065 Heightened Interest from the Medical Research Community and New Funding of International Stem Cell Corporation's (ISCO) Therapeutic Research [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 066 International Stem Cell Corporation Announces the Commercial Launch of Its Breakthrough Stem Cell-Based Line of Skin Care Products [Last Updated On: December 10th, 2010] [Originally Added On: December 10th, 2010]
- 067 International Stem Cell Corporation Announces Commercial Sales to General Public of Its Breakthrough Stem Cell-Based Lines of Skin Care Products [Last Updated On: December 10th, 2010] [Originally Added On: December 10th, 2010]
- 068 International Stem Cell Corporation Announces $25 Million Common Stock Financing Agreement [Last Updated On: December 15th, 2010] [Originally Added On: December 15th, 2010]
- 069 International Stem Cell Corporation Announces Start of Marketing Collaboration with John Mauldin for Skin Care Products [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 070 International Stem Cell Corporation to Present Ethical and Technical Qualities of Human Parthenogenetic Stem Cells at the Center for Ethics in Science [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 071 Two new initiatives from the CSCC [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 072 A difference between normal and cancer SC biology in the nervous system [Last Updated On: January 7th, 2011] [Originally Added On: January 7th, 2011]
- 073 International Stem Cell Corporation Announces Company Update Conference Call [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 074 International Stem Cell Corporation Applauds Research Showing Parthenogenesis as a Potential Strategy for Treating Inherited Disease [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 075 International Stem Cell's Scientists in Collaboration with World Leading Stem Cell Experts Extend Understanding of Human Parthenogenetic Stem Cells... [Last Updated On: January 26th, 2011] [Originally Added On: January 26th, 2011]
- 076 International Stem Cell Corporation: A Multitude Of Potential Products From Its Parthenogenesis Technology by Jason Chew [Last Updated On: February 12th, 2011] [Originally Added On: February 12th, 2011]
- 077 International Stem Cell Corporation Demonstrates Progress in the Use of Immune Matched Human Parthenogenetic Stem Cells to Promote the Development... [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 078 International Stem Cell Corporation: Note From The CEO Andrey Semechkin [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 079 "A Little Egg On the Face" - LifeLine Skin Care Stem Cell Cream Article [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 080 International Stem Cell Corporation Updates on 2010 Initial Product Launch of its Lifeline Skin Care Products [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
